1. Home
  2. CMPX vs JYNT Comparison

CMPX vs JYNT Comparison

Compare CMPX & JYNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CMPX
  • JYNT
  • Stock Information
  • Founded
  • CMPX 2014
  • JYNT 2010
  • Country
  • CMPX United States
  • JYNT United States
  • Employees
  • CMPX N/A
  • JYNT N/A
  • Industry
  • CMPX Biotechnology: Pharmaceutical Preparations
  • JYNT Multi-Sector Companies
  • Sector
  • CMPX Health Care
  • JYNT Miscellaneous
  • Exchange
  • CMPX Nasdaq
  • JYNT Nasdaq
  • Market Cap
  • CMPX 291.8M
  • JYNT 170.3M
  • IPO Year
  • CMPX N/A
  • JYNT 2014
  • Fundamental
  • Price
  • CMPX $3.56
  • JYNT $10.03
  • Analyst Decision
  • CMPX Strong Buy
  • JYNT Strong Buy
  • Analyst Count
  • CMPX 8
  • JYNT 3
  • Target Price
  • CMPX $13.50
  • JYNT $16.33
  • AVG Volume (30 Days)
  • CMPX 978.5K
  • JYNT 80.9K
  • Earning Date
  • CMPX 11-11-2025
  • JYNT 11-06-2025
  • Dividend Yield
  • CMPX N/A
  • JYNT N/A
  • EPS Growth
  • CMPX N/A
  • JYNT N/A
  • EPS
  • CMPX N/A
  • JYNT N/A
  • Revenue
  • CMPX N/A
  • JYNT $53,449,713.00
  • Revenue This Year
  • CMPX N/A
  • JYNT $8.06
  • Revenue Next Year
  • CMPX N/A
  • JYNT $11.18
  • P/E Ratio
  • CMPX N/A
  • JYNT N/A
  • Revenue Growth
  • CMPX N/A
  • JYNT 277.36
  • 52 Week Low
  • CMPX $1.27
  • JYNT $9.58
  • 52 Week High
  • CMPX $4.08
  • JYNT $13.47
  • Technical
  • Relative Strength Index (RSI)
  • CMPX 62.05
  • JYNT 32.68
  • Support Level
  • CMPX $3.37
  • JYNT $9.85
  • Resistance Level
  • CMPX $3.77
  • JYNT $10.74
  • Average True Range (ATR)
  • CMPX 0.19
  • JYNT 0.20
  • MACD
  • CMPX 0.01
  • JYNT -0.05
  • Stochastic Oscillator
  • CMPX 56.25
  • JYNT 19.78

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.

About JYNT The Joint Corp.

The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has one operating business segment; The Franchise Operations segment which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the Company's franchise license, which represents symbolic intellectual property.

Share on Social Networks: